A composition including a mixture of extracts of aromatic plants, and in particular extracts of lemon balm, thyme, rosemary, wormwood and lemongrass, veterinary or pharmaceutical compositions including the composition and a food for non-human animals including the composition. Also, a method for preparing the composition and a method for the prevention or treatment of flea infestation that include the administration of the composition to a domestic mammal.

A recombinant oncolytic virus, a synthetic DNA sequence and applications of the virus. The recombinant oncolytic virus includes a genome and an exogenous DNA sequence inserted in the genome. The exogenous DNA sequence adapts to express a basic peptide fragment, to increase the environmental pH in a host infected by the recombinant oncolytic virus. More than 60% of amino acids in the basic peptide fragment are basic amino acids. The recombinant oncolytic virus and the synthetic DNA sequence of the disclosure are used to prepare an anti-tumor drug.

Described herein are transdermal solvent systems comprising at least one active agent in solution in a base solution, the base solution comprising at least one fatty acid ester compound, at least one monoterpene compound and a co-solvent in the form of DMSO or DMI and at least one plant oil. The base solution was found to be highly versatile and provide superior or at least comparable skin penetration efficacy and active agent compatibility. Methods of treatment, uses of the solvent system and methods of manufacture are also described.

An implant for insertion into a punctum of a patient comprises a body. The body has a distal end, a proximal end, and an axis therebetween. The distal end of the body is insertable distally through the punctum into the canalicular lumen. The body comprises a therapeutic agent included within an agent matrix drug core. Exposure of the agent matrix to the tear fluid effects an effective therapeutic agent release into the tear fluid over a sustained period. The body has a sheath disposed over the agent matrix to inhibit release of the agent away from the proximal end. The body also has an outer surface configured to engage luminal wall tissues so as to inhibit expulsion when disposed therein. In specific embodiments, the agent matrix comprises a non-bioabsorbable polymer, for example silicone in a non-homogenous mixture with the agent.

A dosage-indicating topical formulation and a method of using said formulation is described. The topical formulation includes one or more bioactive substances and a topical dosage indicator. The topical dosage indicator includes one or more colored copper-containing compounds, and has a color that changes as the topical dosage indicator is absorbed into the skin. The copper-containing compound may include, for example, a copper (II) salt or a copper (I) salt; and a complexation agent containing donor atoms acting as ligands, where the donor atoms are selected from the group consisting of one or more of a nitrogen (N) atom, an oxygen (O) atom, a sulfur (S) atom. The method of using the dosage indicating topical formulation includes repeated rubbing portions of the topical formulation into the skin until the change in color indicates that the skin is saturated with the formulation.

The current invention provides a composition for use in the topical treatment and/or prevention of infectious hoof diseases in an animal, wherein composition comprises a medium-chain fatty acid (MCFA) fraction comprising one or more MCFAs and/or derivatives thereof. In a second aspect, the invention provides a method for disinfecting the hoofs of an animal comprising the step of topically administering a composition comprising an MCFA fraction to said animal, wherein said MCFA fraction comprises one or more MCFAs and/or derivatives thereof. In a final aspect, the invention provides a disinfectant composition comprising an MCFA fraction and acarboxylic acid (CA) fraction, wherein said MCFA fraction comprises MCFAs and/or derivatives thereof, and said CA fraction comprises one or more carboxylic acids.

Provided are a benzimidazole compound represented by the general formula (1)

##STR00001##

{wherein R.sup.1 represents a hydrogen atom or a cyano group, R.sup.2 represents a (C.sub.1-C.sub.6) alkyl group, a (C.sub.1-C.sub.6) alkoxy (C.sub.1-C.sub.6) alkyl group, or a halo (C.sub.1-C.sub.6) alkyl group, R represents a (C.sub.1-C.sub.3) alkylene group or a halo (C.sub.1-C.sub.3) alkylene group, and m represents 0, 1, or 2}, or a salt thereof, an agricultural and horticultural insecticide comprising the compound or the salt as an active ingredient; an animal ectoparasite or endoparasite control agent comprising the compound or the salt as an active ingredient; and a method for using the insecticide or the agent.

Described herein are methods and compositions for reducing transmission of Plasmodium to a female mosquito. Aspects of the invention relate to contacting to a mosquito with a Plasmodium transmission blocking compound. Another aspect of the invention relates to a surface coated with a Plasmodium transmission blocking compound.

The present invention relates to Siphoviridae bacteriophage Lac-GAP-3 (Accession Number KCTC 12816BP) having the ability to specifically kill Lactococcusgarvieae bacteria and a genome represented by SEQ ID NO: 1 and isolated from nature, and a method for prevention and treatment of Lactococcusgarvieae bacterial infection by using a composition containing the same bacteriophage as an effective ingredient.

An implant for insertion through a punctum and into a canalicular lumen of a patient. The implant includes a matrix of material, a therapeutic agent dispersed in the matrix of material, a sheath disposed over a portion of the matrix of material and configured to inhibit the therapeutic agent from being released from the matrix of material into the canalicular lumen and to allow the therapeutic agent to be released from a surface of the matrix of material to a tear film, and a retention structure configured to retain the implant within the canalicular lumen.